🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Among women w/ premature MIs, 39% had a history of APO. Women w/ APO history presented sooner after pregnancy but had similar MI characteristics vs those w/out APOs. Pregnancy history may identify women who warrant early, aggressive #cvPrev. bit.ly/3DptAbk #JACCAdvances

Lipoprotein(a) is risk factor for *early* atherosclerosis. Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study #CardioTwitter thelancet.com/journals/landi…

#Tirzepatide lowered HbA1c to less than 7% in 90% of patients with #type2diabetes and #obesity. Even more impressive: HbA1c normalized to <5.7% in half of patients 😲. All this with minimal hypoglycemia. And an average 15.7% weight loss 📉 SURMOUNT-2: thelancet.com/journals/lance…

👉 Colchicine for CV prevention: the dawn of a new era has finally come ☝️“The approval of colchicine for secondary CV prevention definitely represents the dawn of a new era as it is the first approved drug tackling the residual inflammatory risk” doi.org/10.1093/eurhea…

Just out ➡️ Outcomes of Adult Patients With Anomalous RCA #CardioTwitter David L. Fischman Mamas A. Mamas Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Erin D. Michos, M.D. David J. Cohen, MD, MSc Douglas Drachman Dr Roxana Mehran Sunil V. Rao Julia Grapsa MD, PhD Ritu Thamman MD Dr. Deepak L. Bhatt MIЯVΛƬ #IC Harriette Van Spall, MD MPH 🇨🇦 Salvatore Brugaletta Jay Mohan, D.O., FACC, FSCAI, FASE, RPVI sciencedirect.com/science/articl…

Great line from a new patient: “Hi doc. I’m homozygous for a CYP2C19 reduced function allele so you should probably switch me to Prasugrel before PCI. I work in pharmacogenomics BTW but my physician daughter doesn’t believe me. Totally up to you though...” 🤣 #CardioTwitter

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: JACC Journals Guidelines are detailed: reading it slowly Please, read full doc! Thread #14: Medical management: What is going on w antiplatelet therapy? 🥸📷👇

For a 50 year old patient with diabetes & chronic kidney disease, combination treatment with SGLT2 inhibitors & finerenone is projected to result in ~5 additional years free from kidney failure Our cross trial analysis of CREDENCE, DAPA-CKD & FIDELIO: …ubs.pericles-prod.literatumonline.com/doi/10.1111/do…

Check out our editorial in #JACCInterventions discussing an interesting manuscript “PPCI in Patients With #SCAD vs CAD” by Alfonso et al. Editorial: “SCAD Causing AMI: Is Revascularization the Best Course of Action?” 👉sciencedirect.com/science/articl… JACC Journals Jacqueline Saw #AjayKirtane

Multicenter real-world audit of #FFRCT by #YesCCT in UK's NICE guidelines shows that PPV of FFRCT was 49%, & its use was costlier vs stress tests. A cautious approach is implied for FFRCT roll-out in clinical practice. bit.ly/3P2NMq6 #JACCIMG #CardioTwitter

#ESCCongress #JACC LBCT SimPub: New from #DAPA-HF & #DELIVER: Benefit-to-risk ratio may favor continuation of #SGLT2i dapagliflozin in #HeartFailure pts w/ deterioration in kidney function to eGFR<25ml/min/1.73m2 bit.ly/3QU3AwK Safia Chatur, MD Muthu Vaduganathan @scottsolomon

An historic Class 1A recommendation for HFpEF. Expected but still remarkable. #ESCCongress European Society of Cardiology Proud of the many who brought this forward for our patients. Mikhail Kosiborod Saint Luke's Mid America Heart Institute Saint Luke's

Big news #ESC2023 and NEJM In a placebo-controlled randomized trial of people with obesity + heart failure (with preserved ejection fraction). semaglutide (Wegovy) markedly improved symptoms, exercise time, reduced inflammatory markers (and weight loss) nejm.org/doi/full/10.10…

Late breaking at #ESCCongress: In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo. Full STEP-HFpEF trial:

📷 "Honored to be in the company of these exceptional #WomenInCardiology. A memorable evening exchanging stories and charting the course for the WIC community's journey ahead. 💙👩‍⚕️ #CardioQueens #HeartbeatsAndHighHeels" 👠🩺#BarbiesinCardiology😍🥰💃#TCACC

Don’t miss this joint AHA/ACC webinar! Achieving gender equity in cardiology requires collaboration with our male allies! Join us to discuss what #HeForShe means in cardiology ! #AHAWIC #ACCWIC Gina Lundberg MD FACC FAHA Pam R. Taub, MD❤️💃🏻 Renée Bullock-Palmer MD FACC FAHA FASNC FASE FSCCT

Safety of Continuing #MRA Treatment in Patients with #HFrEF and Severe Kidney Disease In this study from the Swedish Heart Failure Registry of 33,942 HFrEF patients (EF < 40%): 📍51% received MRA, with varying rates across #eGFR levels. 📍Higher eGFR & severe HF features

🌟Pub alert! While #preeclampsia (PE)⬆️CVD risk, how do we identify those ♀️whose arteries are already on a disease path? Led by Amélie Paquin ,we showed that PE ♀️who remain HTNsive have much worse arterial health, and may be prioritized for #CVPrev ➡️bit.ly/46pUBIK

Agent ISR- YES!! Nearly three-quarters of the patients had intravascular image guided ISR PCI….and the outcomes were very good. Now that’s progress! Let’s next hope for rapid FDA approval of Agent coupled with wide adoption of intravascular imaging for all ISR cases.

My #Cardiology paper of the year: Daily Step Count in JACC Journals The optimal steps to ⬇️ CVD events is NOT THAT HIGH! Totally achievable! Its easy to get discouraged by the marathoners, bodybuilders, etc. Sure that's great, but not necessary. Do enough, the benefits follow